Clinical trials: Solid Tumors, completed
Pediatric Tumor, Familial Cancer
Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia
Background. Cancer is the leading cause of death by disease in children. Most pediatric tumors differ from adult tumors in terms of biological and clinical characteristics.
- Conditions
- Pediatric Tumor, Familial Cancer, Solid Tumor, Childhood, Hematological Tumor
- Trial name
- ALADIN (NCT04471961)
- Testing
- Exome sequencing in pediatrics cancers
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study
This study determines how the threat of the coronavirus has affected the mental health and physical well-being of cancer patients seen at the psychiatric oncology clinic, and how they have coped with any related stress.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04652505
- Testing
- Questionnaire Administration
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
EXERCISING TOGETHER for Couples Coping With Cancer
The Exercising Together trial is a single-blind, parallel group, randomized controlled trial comparing 3 arms: Arm 1 (experimental): Exercising Together where couples perform partnered exercise in a supervised, group setting…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
- Trial name
- NCT03630354
- Testing
- Exercise Intervention (supervised), Exercise Intervention (unsupervised), Informational Intervention
- Where
- United States
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Tumors, Hematologic Malignancies
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally…
- Trial name
- NCT01375842
- Testing
- Atezolizumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 661 people
- Sponsor
- Genentech, Inc.
Sarcoma, Melanoma
A Study of PRT1419 in Patients With Advanced Solid Tumors
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors.
- Conditions
- Sarcoma, Melanoma, Lung Cancer, Breast Cancer
- Trial name
- NCT04837677
- Testing
- PRT1419
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Prelude Therapeutics Incorporated
Locally Advanced or Metastatic Solid Tumors
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab.
- Trial name
- NCT02722954
- Testing
- Demcizumab, Pembrolizumab
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 29 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Advanced Cancer
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
The purpose of this study is to determine whether corrected QT (QTc) interval changes occur on an electrocardiogram (ECG) when cetuximab is administered to the study population.
- Trial name
- NCT00698841
- Testing
- Cetuximab
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Eli Lilly and Company
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT05753722
- Testing
- PRTH-101, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 79 people
- Sponsor
- Incendia Therapeutics
Advanced or Metastatic Solid Tumors, Advanced or Metastatic Breast Cancer
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
The purpose of this clinical trial is to test whether treatment of patients with advanced or metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in good tumor response.
- Trial name
- VA (NCT00748553)
- Testing
- Azacitidine (Vidaza), Nab-paclitaxel (Abraxane)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
RATIONALE: The herb ginger may help to reduce or prevent nausea and vomiting in patients receiving chemotherapy for cancer. PURPOSE: This randomized phase II trial is studying how well ginger works in reducing or preventing…
- Trial name
- IRB 2003-551 (NCT00064272)
- Testing
- ginger extract
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 180 people
- Sponsor
- University of Michigan Rogel Cancer Center
Stage IV Melanoma, Stage III Melanoma
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have high-risk stage III or completely…
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00019890
- Testing
- dendritic cell-gp100-MART-1 antigen vaccine, sargramostim
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of…
- Trial name
- NCT02122913
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bayer
Cancer
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety in patients with cancer.
- Trial name
- NCT01611623
- Testing
- SNX-5422
- Volunteers
- 9 people
- Sponsor
- Esanex Inc.
Advanced Solid Cancers
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in…
- Trial name
- NCT03956680
- Testing
- BMS-986301, Nivolumab, Ipilimumab
- Where
- 5 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Multiple Myeloma
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
This study will look for the highest tolerated dose of dalotuzumab (MK-0646) given as weekly, every other week. or a every three week infusion.
- Trial name
- NCT00701103
- Testing
- Dalotuzumab
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer, Solid Tumor
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied.
- Trial name
- NCT01596140
- Testing
- Vemurafenib, Everolimus, Temsirolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I study with escalating doses of PM060184 in combination with gemcitabine in selected patients with advanced solid tumors.
- Trial name
- NCT02533674
- Testing
- Gemcitabine plus PM060184
- Where
- 2 sites in United States, Spain
- Volunteers
- 57 people
- Sponsor
- PharmaMar
Neoplasm of Uncertain Malignant Potential, Unspecified Childhood Solid Tumor, Protocol Specific
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b in treating young patients with plexiform…
- Trial name
- NCT00253474
- Testing
- PEG-interferon alfa-2a
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Neoplasm Metastasis, Carcinoma
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
This study will evaluate PTK787, a new oral drug that stops blood vessel development, in combination with Paclitaxel in patients with advanced solid tumors.
- Trial name
- NCT00731861
- Testing
- Paclitaxel plus PTK787
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Indiana University
Adult Solid Neoplasm, Estrogen Receptor Negative
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors.
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT01281150
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.